delpacibart braxlosiran

News

Novartis' $12bn takeover of Avidity could potentially give it the first therapy for genetic disorder facioscapulohumeral muscular dystrophy.

News

Armed with new pivotal trial results, Eli Lilly is preparing to file for approval of its triple-acting weight-loss therapy, retatrutide, next year.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.